Eupraxia Pharmaceuticals IncEPRX
Price$7.83

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$38.6MTTM through 31 Dec 2025
Free Cash Flow -$28.6MTTM through 31 Dec 2025

Margins

Current

Returns

-47.0%ROE
-44.8%ROA

Balance Sheet Health

Current Ratio15.12x
Cash & Equivalents$80.6M

Quality Metrics

Altman Z-Score56.51
Piotroski F-Score3 / 9
Earnings-Beat Rate33.3%

Dividend

No dividend

Capital Allocation

R&D Spend$21.3M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.